11 research outputs found
A novel antifungal protein from seeds of Sesbania virgata (Cav.) Pers. (Leguminosae-Faboideae)
A novel antifungal protein from seeds of Sesbania virgata (Cav.) Pers. (Leguminosae-Faboideae)
A novel antifungal protein with a molecular mass around 50 kDa was purified from seeds of Sesbania virgata (Cav.) Pers. using ammonium sulfate fractionation followed by gel filtration on a Sephadex G-75 Superfine (Sigma) column and reverse-phase high performance liquid chromatography on a C8 column. The protein, designated FP1-A, with a novel N-terminal sequence AMVHSPGG(S)FS(P), showed growth inhibitory activity of filamentous fungi Aspergillus niger, Cladosporium cladosporioides, Colletotrichum gloeosporioides and Fusarium solani
A novel antifungal protein from seeds of Sesbania virgata (Cav.) Pers. (Leguminosae-Faboideae)
A novel antifungal protein with a molecular mass around 50 kDa was purified from seeds of Sesbania virgata (Cav.) Pers. using ammonium sulfate fractionation followed by gel filtration on a Sephadex G-75 Superfine (Sigma) column and reverse-phase high performance liquid chromatography on a C8 column. The protein, designated FP1-A, with a novel N-terminal sequence AMVHSPGG(S)FS(P), showed growth inhibitory activity of filamentous fungi Aspergillus niger, Cladosporium cladosporioides, Colletotrichum gloeosporioides and Fusarium solani
Assessment of psychometric properties of the Brazilian version of the oral anticoagulation knowledge test
Adaptação Transcultural do Oral Anticoagulation Knowledge Test para o PortuguĂȘs do Brasil
Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach
Dysferlinopathy is a muscular dystrophy with a highly variable functional disease progression in which the relationship of function to some patient reported outcome measures (PROMs) has not been previously reported. This analysis aims to identify the suitability of PROMs and their association with motor performance.Two-hundred and four patients with dysferlinopathy were identified in the Jain Foundation's Clinical Outcome Study in Dysferlinopathy from 14 sites in 8 countries. All patients completed the following PROMs: Individualized Neuromuscular Quality of Life Questionnaire (INQoL), International Physical Activity Questionnaire (IPAQ), and activity limitations for patients with upper and/or lower limb impairments (ACTIVLIMs). In addition, nonambulant patients completed the Egen Klassifikation Scale (EK). Assessments were conducted annually at baseline, years 1, 2, 3, and 4. Data were also collected on the North Star Assessment for Limb Girdle Type Muscular Dystrophies (NSAD) and Performance of Upper Limb (PUL) at these time points from year 2. Data were analyzed using descriptive statistics and Rasch analysis was conducted on ACTIVLIM, EK, INQoL. For associations, graphs (NSAD with ACTIVLIM, IPAQ and INQoL and EK with PUL) were generated from generalized estimating equations (GEE). The ACTIVLIM appeared robust psychometrically and was strongly associated with the NSAD total score (Pseudo R2 0.68). The INQoL performed less well and was poorly associated with the NSAD total score (Pseudo R2 0.18). EK scores were strongly associated with PUL (Pseudo R2 0.69). IPAQ was poorly associated with NSAD scores (Pseudo R2 0.09). This study showed that several of the chosen PROMs demonstrated change over time and a good association with functional outcomes. An alternative quality of life measure and method of collecting data on physical activity may need to be selected for assessing dysferlinopathy